Latest Healthcare Sector News

Vita Life Sciences projects a slight increase in H1 2026 sales and stable pre-tax profits, supported by strong markets in Australia and Malaysia/Singapore but offset by regulatory headwinds in China.

ReNerve Limited has appointed UG Medical to distribute its NervAlign nerve repair products in Malaysia, tapping into a fast-growing healthcare market backed by government investment.

Stakk Ltd has secured a significant U.S. healthcare technology contract, pushing its annualised revenue run rate to approximately A$26 million. The deal highlights accelerating adoption of its AI-native Digital Trust platform across regulated industries.

Little Green Pharma has secured Federal Court approval for its full acquisition of Cannatrek, marking a key milestone in expanding its global medicinal cannabis footprint. The scheme became effective on 25 May 2026, with implementation set for 1 June.

IMEXHS has landed a significant public tender in Mexico, deploying its AI-powered Aquila+ radiology platform across 20 hospitals, adding $384,000 in new annual recurring revenue and advancing its Latin American expansion.

Ex-CEO Geoff Cockerill has initiated court proceedings against Vitura Limited, alleging breaches of the Fair Work Act related to his January 2026 departure. Vitura maintains all contractual obligations were met and plans to resolve the dispute swiftly.

Alcidion Group has acquired Telstra Health's Kyra flow products for $3 million upfront, adding 33 long-term customers and boosting recurring revenue in key Australian states.

Algorae Pharmaceuticals has scaled its AI-driven drug synergy platform from one to 18 anchor drugs, generating over 9 million predictions and identifying thousands of promising combinations for cancer and other diseases.

Despite sweeping changes to Capital Gains Tax announced in the 2026/27 Federal Budget, Acrux Limited’s status as a Pooled Development Fund ensures its shareholders remain shielded from these new tax rules.

Barramundi Limited outperformed the S&P/ASX200 in April with a 4.4% gross return, boosted by NEXT DC’s landmark data centre deal and capital raise, while healthcare stocks faced headwinds from Cochlear’s profit downgrade.

The Hydration Pharmaceuticals Company Limited (ASX: HPC) temporarily halted trading to relodge its FY25 Annual Report, revealing a $2.86 million loss driven by US market rationalisation and ongoing cost-cutting.

IMEXHS Limited kicked off FY26 with a 13% revenue increase and a strategic pivot to an AI-native radiology workflow platform, securing major contracts in Latin America and advancing proprietary AI agents.